The cytoskeleton not only plays an important role in maintaining cellular morphology and maintaining the internal structure of the cell to withstand external forces, but also participates in many important life activities. The physiological structure, function and distribution of cytoskeletal proteins and their abnormal expression are closely related to the development of neurological and renal diseases. With in-depth knowledge of cytoskeleton-related fields and extensive project experience, CD BioSciences provides reference materials on Parkinson's Disease to help you learn more about our various testing services and welcome you to contact us directly for more specific solutions.
Mechanisms of Parkinson's Disease
The symptoms of dyskinesia in Parkinson's disease are due to the loss of dopamine-secreting pigment cells in the dense region of the substantia nigra. The substantia nigra is a very small area located deep in the brain, and in PD patients, these dopaminergic nerve cells of the substantia nigra degenerate and die, and only fewer live neurons are observed in this area in PD brain tissue than in normal brain tissue. lack of dopamine in PD patients disrupts motor control and the patient's mood, behavior, thinking and feeling.
Multi-system and multi-neurotransmitter dysfunction in PD [1].
Cell Biology of LRRK2 in Parkinson's Disease
Although most cases of PD are idiopathic, approximately 5% to 10% are familial with a clear autosomal inheritance pattern. Point mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of autosomal inherited PD. LRRK2 has been shown to interact physically or genetically with many other PD genes. Mutant LRRK2 can cause synucleinopathies, with abnormal aggregation of α-synuclein, as well as tauopathies, with abnormal aggregation of the microtubule-associated protein tau. How LRRK2 mutations drive α-synuclein and tau aggregation requires further investigation.
Interaction of LRRK2 with key PD-related genes [2].
Our Services
Parkinson's disease (PD) is a chronic neurodegenerative disease that affects the central nervous system, causing negative health effects and reducing life expectancy and quality of life. CD BioSciences provides the most comprehensive services for Parkinson's programs. Through rigorous monitoring and effective execution, we are committed to providing the best value solution to complete your project.
- Parkinson's Disease Model Construction
We offer customizable Parkinson's animal model builds, as well as common Parkinson's models such as MPTP-induced mouse models and SNCA transgenic mouse models, to help you complete your own relevant research.
- Evaluation of Parkinson's Disease Models
- Behavioral Analysis
- Imaging Analysis: MRI & SPECT
- Biomarker Analysis: Dopamine and Metabolites
- Levodopamine Treatment: Positive Drug Therapy to Reduce Parkinson's Symptoms
- Pathological Analysis: Immunohistochemical Staining (Tyrosine Hydroxylase Neuron Staining)
- Cytoskeletal Antibody Development for Parkinson's Disease
We develop and produce antibodies related to the above genes, which are widely available to academics and customers in various fields to accelerate the development of therapies for Parkinson's patients.
- Cytoskeletal Compounds Screening for Parkinson's Disease
We have a well-established compound screening process and an extensive compound library to help our clients conduct disease-related research by providing compound screening services for Parkinson's disease-related proteins.
Our Advantages
Advanced Biotechnology
Customizable Designs
Competitive Pricing
Best After-sales Service
CD BioSciences provides our global customers with cost effective, high quality and efficient research solutions for cytoskeleton related diseases. We guarantee on-time delivery of our products and results, please contact us for more details.
References
- Titova N, et al. Parkinson's: a syndrome rather than a disease? [J]. Journal of Neural Transmission, 2017, 124(8): 907-914.
- Usmani A, et al. The Cell Biology of LRRK2 in Parkinson's disease[J]. Molecular and Cellular Biology, 2021, 41(5): e00660-20.
For research use only. Not intended for any clinical use.
